fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Glucagon (02243297). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Glucagon

Form:

2 of 2 products shown

1 Limited Use · 1 listing conditions apply

Baqsimi · DIN 02492415 · 3 mg · Nas Pd Device

Limited Use, Reason for Use code 625 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 625 required
Write on scriptReason for Use code 625 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 625
Reason for Use code 625 For the treatment of severe hypoglycemia (SH) reactions in patients with diabetes mellitus who are receiving insulin therapy and are at high risk for SH, when impaired consciousness precludes oral carbohydrate. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Baqsimi · DIN 02492415 Manufacturer: Amphastar Pharmaceuticals Inc.; listing date 2022-01-31 Health Canada: Marketed since 2024-09-23 · brand BAQSIMI · ATC H04AA01 GLUCAGON · form Powder · route Nasal · ingredients GLUCAGON 3 MG/CONTAINER · company Amphastar pharmaceuticals, inc. · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Baqsimi: Formulary list price $160.52 per unit (the source does not state the unit; exact figure $160.5200). What the ministry pays, not the patient.

Ministry pays: $160.5200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02492415)

Source record
DIN 02492415: Baqsimi Raw flags: sec12=Y, sec3=Y Item: 920000739; group id 920; item number 2194; lccId 00351; manufacturer id AMP Source form: Nas Pd Device; strength: 3mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $160.5200; ministry $160.5200 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02492415 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98243
Shortage status: resolved shortage (ended August 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492415
Shortage record checked October 6, 2026

Glucagon Injection Kit · PIN 09858279 · 1 mg/Vial · injection Pd-1mL vial (Kit)

Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
No interchangeable product listed in the Ontario extract
Glucagon Injection Kit · DIN 09858279 Manufacturer: Amphastar Pharmaceuticals Inc.; listing date 2023-09-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Glucagon Injection Kit: Formulary list price $280.00 per unit (the source does not state the unit; exact figure $280.0000). What the ministry pays, not the patient.

Ministry pays: $280.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858279)

Source record
DIN 09858279: Glucagon Injection Kit Raw flags: sec3c=Y Item: 920000743; group id 919; item number 2193; lccId None; manufacturer id AMP Source form: Inj Pd-1mL Vial Pk (Kit); strength: 1mg/Vial Recorded listing: Temporary benefit (shortage substitute) Source prices (unrounded): $280.0000; ministry $280.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858279 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858279
Shortage record checked October 6, 2026

Glucagon rdna origin

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

GlucaGen HypoKit · DIN 02333627 · 1 mg/Vial · injection Pd-Syr Pk

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.Discontinued February 29, 2024 · checked October 5, 2026
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
No interchangeable product listed in the Ontario extract
GlucaGen HypoKit · DIN 02333627 Manufacturer: Novo Nordisk Canada Inc; listing date 2011-12-15 Health Canada: Cancelled post market since 2024-02-29 · brand GLUCAGEN HYPOKIT · ATC H04AA01 GLUCAGON · form Kit, Powder for solution · route Intramuscular · ingredients GLUCAGON (RECOMBINANT DNA ORIGIN) (GLUCAGON HYDROCHLORIDE) 1 MG/VIAL · company Novo nordisk canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

GlucaGen HypoKit: Formulary list price $112.67 per unit (the source does not state the unit; exact figure $112.6700). What the ministry pays, not the patient.

Ministry pays: $112.6700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333627)

Source record
DIN 02333627: GlucaGen HypoKit Raw flags: sec3=Y Item: 920000644; group id 921; item number 2195; lccId None; manufacturer id NOO Source form: Inj Pd-Syr Pk; strength: 1mg/Vial Recorded listing: General benefit Source prices (unrounded): $112.6700; ministry $112.6700 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333627 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81924
Shortage status: discontinued (February 29, 2024, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333627
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 29, 2024 — choose a marketed DIN from the same-category list.

GlucaGen · DIN 02333619 · 1 mg/Vial · powder for injection, vial

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.Discontinued February 29, 2024 · checked October 5, 2026
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
No interchangeable product listed in the Ontario extract
GlucaGen · DIN 02333619 Manufacturer: Novo Nordisk Canada Inc; listing date 2011-12-15 Health Canada: Cancelled post market since 2024-02-29 · brand GLUCAGEN · ATC H04AA01 GLUCAGON · form Kit, Powder for solution · route Intramuscular · ingredients GLUCAGON (RECOMBINANT DNA ORIGIN) (GLUCAGON HYDROCHLORIDE) 1 MG/VIAL · company Novo nordisk canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

GlucaGen: Formulary list price $108.33 per unit (the source does not state the unit; exact figure $108.3300). What the ministry pays, not the patient.

Ministry pays: $108.3300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333619)

Source record
DIN 02333619: GlucaGen Raw flags: sec3=Y Item: 920000643; group id 921; item number 2196; lccId None; manufacturer id NOO Source form: Inj Pd-Vial Pk; strength: 1mg/Vial Recorded listing: General benefit Source prices (unrounded): $108.3300; ministry $108.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333619 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81923
Shortage status: discontinued (February 29, 2024, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333619
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 29, 2024 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 77 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS BAQSIMI is indicated for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates. 1.1 Pediatrics Pediatrics (<18 years of age): BAQSIMI is indicated in children 4 years and above. BAQSIMI has not been studied in pediatric patients less than 4 years of age. The number of pediatric patients (4 to <18 years) included in the clinical trials is limited (n=48) (see WARNINGS AND PRECAUTIONS, Special Populations, DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY, and CLINICAL TRIALS). 1.2 Geriatrics Geriatrics (≥65 years of age): Clinical studies of BAQSIMI did not include sufficient numbers of subjects aged 65 and over. Limited clinical trial experience with BAQSIMI has not identified differences in responses between the elderly and younger patients (see WARNINGS AND PRECAUTIONS, Special Populations; DOSAGE AND ADMINISTRATION; and ACTION AND CLINICAL PHARMACOLOGY). https://pdf.hres.ca/dpd_pm/00074561.PDF PM date: not printed or not captured Source product: BAQSIMI; DIN 02492415; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

GlucaGen HypoKit · DIN 02333627 Shortage status: discontinued (2024-02-29, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333627

Check this DIN again

GlucaGen · DIN 02333619 Shortage status: discontinued (2024-02-29, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333619

Check this DIN again